抽象的な

Treatment of cutaneous and mucosal HPV lesions with Interferon (IFN) recombinant human -Α2b in pediatric patients.

María Fernanda Rolotti*, Carolina Bello, María Sofia Granillo Fernandez, Ana Garone, Lucrecia Torres Molina and Alicia Rositto

Recombinant human interferon alpha 2b (IFNα2b) is a therapeutic alternative for the treatment of Human papillomavirus (HPV) lesions. The medical records of 45 children and adolescents who received 300,000 IU intralesional or subcutaneous IFNα2b every two months for the treatment of recalcitrant HPV lesions were evaluated. A longitudinal retrospective observational study was conducted in the period between 02/01/2014 and 09/30/2015. Results: of the 45 patients evaluated, 7 abandoned the controls, so the final sample consisted of 38 patients. 52.6% women and 47.4% men. 81.5% of the patients presented clinical improvement. 42.1% had a total response and 39.4% had a partial response. 15.8% of the patients had no response. 2.7% of the patients showed relapse and no patient presented progression. Conclusion: We used IFNα2b 300,000 IU per application with an interdose interval greater than those published to date. The results obtained were similar for both administration routes. No adverse effects were recorded with the dose used. IFNα2b turned out to be an affordable medication. The majority of patients presented some degree of clinical improvement.